Previous 10 | Next 10 |
home / stock / dsnky / dsnky news
2023-10-26 09:00:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. A historically wide di...
2023-10-26 08:45:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. A historically wide di...
2023-10-26 07:05:54 ET More on Merck Merck & Co. Inc. (MRK) Merck & Co. Announced Collaboration with Daiichi Sankyo and ESMO Investor Event (Transcript) Merck Q3 2023 Earnings Preview: Keytruda LOE Continues To Dominate Narrative Merck: Right On Time ...
2023-10-23 09:02:58 ET Summary Daiichi Sankyo has entered into a collaboration with Merck for three antibody-drug conjugates, bringing in a significant upfront payment and potential milestone payments. The three drugs in development, targeting HER3, B7-H3, and CDH6, have shown pro...
2023-10-23 06:09:11 ET Summary Daiichi Sankyo is a Japanese pharmaceutical company known for its flagship products Lixiana and Enhertu. Enhertu is becoming a popular treatment for breast cancer, based on technology that is substituting chemotherapy. Long-term earnings outlook ...
2023-10-22 09:00:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. We have been surprised...
2023-10-20 11:12:54 ET More on Merck Merck: Right On Time Merck Vs. GSK: The Game-Changer Race In Pharma Excellence Merck: Still Fundamentally Undervalued Considering Keytruda's Prospects Merck study shows Keytruda can help lower death risk from cervical canc...
2023-10-19 23:52:31 ET More on Daiichi, Merck, etc. Merck: Right On Time Merck Vs. GSK: The Game-Changer Race In Pharma Excellence Merck: Still Fundamentally Undervalued Considering Keytruda's Prospects AstraZeneca drops after Phase 3 data for lung cancer the...
2023-10-18 10:25:26 ET More on AstraZeneca, Daiichi, etc. AstraZeneca: Hidden Gem Of The Pharma Sector Is A Great Buy Opportunity AbbVie Vs. AstraZeneca: Battle Of The Pharmaceutical Behemoths Daiichi Sankyo Company, Limited (DSKYF) Q1 2023 Earnings Call Transcript ...
2023-10-13 11:00:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. A historically wide di...
News, Short Squeeze, Breakout and More Instantly...
Daiichi Sankyo Co Ltd Sponsored ADR Level 1 Company Name:
DSNKY Stock Symbol:
OTCMKTS Market:
AstraZeneca plc (NASDAQ:AZN) reported topline data from a metastatic breast cancer treatment study. The results showed that Enhertu (t...
On Friday, the FDA approved Daiichi Sankyo Ltd’s (OTC:DSKYF) (OTC:DSNKY) and AstraZeneca Plc’s (NASDAQ:AZN) Enhertu...
Pfizer Inc (NYSE:PFE) is set to announce its fourth quarter 2023 earnings next week on 30th January. The analysts expect the US pharma giant to re...